SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.54-3.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (5517)1/22/2002 1:08:30 PM
From: Biomaven  Read Replies (2) of 52153
 
Jon,

The ELN news was very sad. I'd heard a lot of AD researchers were pretty excited about this program. I've heard a suggestion that it may be some sort of auto-immune reaction, in which case the drug is likely near dead. The fact that it occurred in only one subgroup does leave some lingering hope that there was some sort of fixable contamination. I suppose there's always the possibility that they could dose it with steroids, although that would complicate approval greatly.

My guess is that we may also be seeing some Enron fallout in ELN. ELN has always been a favorite of the shorts, and they probably seized on the confluence of Enron and this failure to attack the stock. Even though this was an early-stage project, it was one with enormous potential and a very high profile.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News